Nalagenetics was built with the passion to give access to personalized prescription to as many people as possible. Two of the co-founders have seen and felt firsthand the betrayal of drugs that were supposed to cure their family members, but instead caused them permanent side effects. It was then that we realized, without understanding how to best use them, innovations in pharma and biotech, meant little to the people who need it most. There is a field, pharmacogenomics, that studies the relationship of genomics and drug metabolism. We think the reason why this isn’t yet adopted in the region is because of low cost effectiveness: compared to status quo, current interventions are too expensive for an effect that is not well measured.Something looks off?